undamentalytics Newsletter

Riker Lauren: insider trades

Officer at Pacira Biosciences, Inc. No open-market purchases and 22 sales not made under a pre-set plan, reported from March 18, 2013 to June 5, 2025.

What happened after Riker Lauren’s sales?

After their sales, the shares moved −7.3% against the index over 12 months on average (a negative figure means selling was the right call); 68% trailed it.

With 296 insiders tested, some will look skilled or unskilled by chance alone: when we replaced each insider’s stocks with random companies bought on the same days, about 5.7 cleared the bar ahead and 23.3 behind. One record on its own proves little.

Trade by trade

Riker Lauren: trades against the S&P 500 afterwards
MeasuredTrades countedAverage vs S&P 500MedianWent the right wayYearst-statisticp-valueEvidence
Purchases, 3 months after the report 0 — — — — — — Not enough years
Purchases, 6 months after the report 0 — — — — — — Not enough years
Purchases, 12 months after the report 0 — — — — — — Not enough years
Purchases, 12 months after the trade 0 — — — — — — Not enough years
Sales, 3 months after the report 22 −6.5% −12.8% 73% 11 −1.83 0.097 No reliable evidence
Sales, 12 months after the report 22 −7.3% −9.6% 68% 11 −0.38 0.71 No reliable evidence
Sales, 12 months after the trade 22 −8.9% −8.7% 68% 11 −0.73 0.48 No reliable evidence

“Average vs S&P 500” is the stock’s return including dividends minus the index’s over the same dates, from the close on the first trading day after the report, or from the close on the trade date. Only windows that have finished are counted. For sales, a negative figure means the stock lagged after it was sold, so selling was the right call (green). “Went the right way” is the share of purchases that beat the index, or of sales that trailed it. The t-statistic uses one average per year of reports, because one person’s trades bunch into the same stock and weeks, and needs trades in at least four different years; the p-value comes from the t distribution with that number of years (with four years, a t of 2 has p = 0.14). “Some evidence” means p under 5%, “strong evidence” p under 1% over at least six years.

Companies traded

CompanyTitle on the latest filingPurchasesSalesFirst reportLatest report
Pacira Biosciences, Inc. PCRX Senior Vice President, Finance022March 18, 2013June 5, 2025

Trades and what followed

Moves are against the S&P 500; green means the trade went the insider’s way.

ReportedTradedCompanyTradeValue3 months after report12 months after report12 months after trade
June 5, 2025June 4, 2025 PCRX Sale $146,208 −5.6%−35.1%−40.9%
June 7, 2023June 6, 2023 PCRX Sale $46,371 −13.0%−48.7%−52.2%
June 8, 2022June 6, 2022 PCRX Sale $70,576 −3.7%−46.4%−43.4%
March 14, 2022March 10, 2022 PCRX Sale $662,331 −15.1%−35.7%−38.0%
June 11, 2021June 11, 2021 PCRX Sale $119,880 −12.8%+1.7%−0.9%
June 8, 2021June 4, 2021 PCRX Sale $63,909 −14.1%−1.4%+7.1%
March 17, 2021March 15, 2021 PCRX Sale $251,406 −21.2%−8.6%−9.3%
August 13, 2020August 11, 2020 PCRX Sale $494,890 −5.9%−40.7%−40.6%
June 8, 2020June 4, 2020 PCRX Sale $125,468 +21.8%−5.6%−8.0%
May 21, 2020May 19, 2020 PCRX Sale $176,140 +19.6%+3.3%+7.6%
November 22, 2019November 20, 2019 PCRX Sale $51,909 −1.4%+23.0%+31.4%
November 12, 2019November 11, 2019 PCRX Sale $217,950 +6.9%+25.5%+18.7%
June 12, 2019June 10, 2019 PCRX Sale $94,139 −20.0%−10.6%−2.6%
June 6, 2019June 4, 2019 PCRX Sale $41,494 −23.0%−5.0%−7.4%
August 24, 2018August 22, 2018 PCRX Sale $74,148 +15.4%−21.6%−20.8%
June 6, 2018June 4, 2018 PCRX Sale $26,449 +19.6%+11.9%+23.1%
December 18, 2017December 15, 2017 PCRX Sale $14,858 −22.3%+8.8%+2.9%
June 9, 2017June 7, 2017 PCRX Sale $49,650 −14.0%−25.6%−32.2%
June 7, 2017June 5, 2017 PCRX Sale $26,035 −20.0%−32.7%−35.2%
June 8, 2016June 6, 2016 PCRX Sale $44,706 −12.9%−19.8%−26.1%
March 18, 2015March 16, 2015 PCRX Sale $476,700 −22.0%−51.1%−47.1%
March 18, 2013March 14, 2013 PCRX Sale $300,000 +1.8%+153.9%+117.4%

Open-market purchases and sales of at least $10,000 in companies we cover, from SEC Form 4 filings; sales made under a pre-set Rule 10b5-1 plan are not shown. “Not yet” means the window has not finished or the share price was under $5 at entry. These are the shares’ moves after each trade: they say nothing about why Riker Lauren traded and do not suggest the use of non-public information. How every insider compares · the insider trading backtest.